Gut metatranscriptomics based de novo assembly reveals microbial signatures predicting immunotherapy outcomes in non-small cell lung cancer

Gut metatranscriptomics based de novo assembly reveals microbial signatures predicting immunotherapy outcomes in non-small cell lung cancer

Abstract Background Advanced-stage non-small cell lung cancer (NSCLC) poses treatment challenges, with immune checkpoint inhibitors (ICIs) as the main therapy. Emerging evidence suggests the gut microbiome significantly influences ICI efficacy. This study explores the link between the gut microbiome...

Full description

Bibliographic Details
Main Authors: David Dora, Peter Kiraly, Csenge Somodi, Balazs Ligeti, Edit Dulka, Gabriella Galffy, Zoltan Lohinai
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Journal of Translational Medicine
Subjects:
Metatranscriptome
De novo assembly
Gut microbiome
Immunotherapy
Immune-checkpoint inhibitor
Progression-free survival
Online Access:https://doi.org/10.1186/s12967-024-05835-y

Internet

https://doi.org/10.1186/s12967-024-05835-y

Similar Items